Your browser doesn't support javascript.
loading
How I treat primary cutaneous CD30+ lymphoproliferative disorders.
Shinohara, Michi M; Shustov, Andrei.
Afiliação
  • Shinohara MM; Division of Dermatology and.
  • Shustov A; Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.
Blood ; 134(6): 515-524, 2019 08 08.
Article em En | MEDLINE | ID: mdl-31164331
The primary cutaneous CD30+ lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases. In the majority of patients, the prognosis of primary cutaneous CD30+ lymphoproliferative disorders is excellent; however, relapses are common, and complete cures are rare. Skin-directed and systemic therapies are used as monotherapy or in combination to achieve the best disease control and minimize overall toxicity. We discuss 3 distinct presentations of primary cutaneous CD30+ lymphoproliferative disorder and present recommendations for a multidisciplinary team approach to diagnosis, evaluation, and management of these conditions in keeping with existing consensus guidelines.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Antígeno Ki-1 / Transtornos Linfoproliferativos Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Antígeno Ki-1 / Transtornos Linfoproliferativos Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article